Previous close | 73.01 |
Open | 73.25 |
Bid | 72.00 x 100 |
Ask | 77.01 x 100 |
Day's range | 73.20 - 73.87 |
52-week range | 71.37 - 87.87 |
Volume | |
Avg. volume | 7,612,972 |
Market cap | 91.253B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 16.28 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.08 (4.21%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
FOSTER CITY, Calif., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
FOSTER CITY, Calif. & WALTHAM, Mass., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
FOSTER CITY, Calif., March 22, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment to br